Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target lifted by stock analysts at JPMorgan Chase & Co. from ...

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD. And retail traders should know.

Bearish flow noted in Gilead (GILD) with 1,949 puts trading, or 1.3x expected. Most active are 4/4 weekly 107 puts and Apr-25 109 puts, with ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $130.00.

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ ... The NASDAQ Index closed more than 10% below its December high of 20,174 on March 6, 2025.

This article is based on a press release statement from Gilead Sciences. While trading at a relatively high earnings multiple, InvestingPro data suggests the company maintains strong cash flows and ...

This article is based on a press release statement from Gilead Sciences. While trading at a relatively high earnings multiple, InvestingPro data suggests the company maintains strong cash flows ...

After Gilead Sciences' lenacapavir made waves with stellar ... according to Baeten. Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch In the phase 1 study ...